Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21041506rdf:typepubmed:Citationlld:pubmed
pubmed-article:21041506lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C0332464lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C0370215lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C2827424lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C0332185lld:lifeskim
pubmed-article:21041506lifeskim:mentionsumls-concept:C2001521lld:lifeskim
pubmed-article:21041506pubmed:issue1lld:pubmed
pubmed-article:21041506pubmed:dateCreated2010-12-24lld:pubmed
pubmed-article:21041506pubmed:abstractTextThe in vitro activity of ceftaroline was compared with those of ceftriaxone, clindamycin, imipenem, metronidazole, moxifloxacin, tigecycline, and vancomycin against 514 clinical anaerobic isolates using Clinical and Laboratory Standards Institute (CLSI) standard methodology. Ceftaroline demonstrated good to excellent activity against Gram-positive anaerobic pathogens and limited activity against Gram-negative pathogens, particularly Bacteroides fragilis group isolates.lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:languageenglld:pubmed
pubmed-article:21041506pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:citationSubsetIMlld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21041506pubmed:statusMEDLINElld:pubmed
pubmed-article:21041506pubmed:monthJanlld:pubmed
pubmed-article:21041506pubmed:issn1098-6596lld:pubmed
pubmed-article:21041506pubmed:authorpubmed-author:SnydmanDavid...lld:pubmed
pubmed-article:21041506pubmed:authorpubmed-author:McDermottLaur...lld:pubmed
pubmed-article:21041506pubmed:authorpubmed-author:JacobusNilda...lld:pubmed
pubmed-article:21041506pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21041506pubmed:volume55lld:pubmed
pubmed-article:21041506pubmed:ownerNLMlld:pubmed
pubmed-article:21041506pubmed:authorsCompleteYlld:pubmed
pubmed-article:21041506pubmed:pagination421-5lld:pubmed
pubmed-article:21041506pubmed:dateRevised2011-8-1lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:meshHeadingpubmed-meshheading:21041506...lld:pubmed
pubmed-article:21041506pubmed:year2011lld:pubmed
pubmed-article:21041506pubmed:articleTitleIn vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.lld:pubmed
pubmed-article:21041506pubmed:affiliationDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Department of Medicine, Tufts School of Medicine, Boston, MA 02111, USA. dsnydman@tuftsmedicalcenter.orglld:pubmed
pubmed-article:21041506pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21041506pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed